Dayton Misfeldt

Dayton Misfeldt is a Partner at Decheng Capital, a global venture capital firm specializing in life sciences and healthcare investments, with a primary focus on early- and growth-stage biopharmaceutical companies. Since joining Decheng Capital in January 2021, he has been actively involved in evaluating investment opportunities and advising portfolio companies on strategic growth, financing, and exit strategies.

Prior to Decheng, Misfeldt spent two decades at Bay City Capital, where he concentrated on investments in the biopharmaceutical industry and played a key role in supporting company management teams, business development, and positioning firms for acquisitions or public offerings. He has served on the boards of several biotechnology companies, including Excellergy Therapeutics and Upstream Bio, and was involved in successful exits such as Cadence Pharmaceuticals, Dermira, Civitas Therapeutics, and others.

Misfeldt began his career as a biopharmaceutical industry analyst at Roth Capital Partners and in consulting at LifeScience Economics. He holds a BA in Economics from the University of California, San Diego, and is recognized for his expertise in biopharma investing and guiding companies operating at the intersection of science and healthcare innovation.